Clinical data also suggest that BCL6B methylation correlates with advanced tumor stage, lymph node metastasis, and 5-fluorouracil (5-FU) resistance, indicating its value as a prognostic and predictive biomarker for chemotherapy response. The gene discussed is BCL6B; the disease is neoplasm.